CA2298107A1 - Use of transcription factor brn-3a - Google Patents

Use of transcription factor brn-3a Download PDF

Info

Publication number
CA2298107A1
CA2298107A1 CA002298107A CA2298107A CA2298107A1 CA 2298107 A1 CA2298107 A1 CA 2298107A1 CA 002298107 A CA002298107 A CA 002298107A CA 2298107 A CA2298107 A CA 2298107A CA 2298107 A1 CA2298107 A1 CA 2298107A1
Authority
CA
Canada
Prior art keywords
brn
vector
polynucleotide
polypeptide
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002298107A
Other languages
English (en)
French (fr)
Inventor
Martin Damian Smith
David Seymour Latchman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biovex Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9715823.2A external-priority patent/GB9715823D0/en
Application filed by Individual filed Critical Individual
Publication of CA2298107A1 publication Critical patent/CA2298107A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • C07K14/4705Regulators; Modulating activity stimulating, promoting or activating activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/028Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a herpesvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA002298107A 1997-07-25 1998-07-27 Use of transcription factor brn-3a Abandoned CA2298107A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9715823.2 1997-07-25
GBGB9715823.2A GB9715823D0 (en) 1997-07-25 1997-07-25 Use of transcription factor BRN-3A
US98847697A 1997-12-10 1997-12-10
US988,476 1997-12-10
PCT/GB1998/002228 WO1999005272A1 (en) 1997-07-25 1998-07-27 Use of transcription factor brn-3a

Publications (1)

Publication Number Publication Date
CA2298107A1 true CA2298107A1 (en) 1999-02-04

Family

ID=26311947

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002298107A Abandoned CA2298107A1 (en) 1997-07-25 1998-07-27 Use of transcription factor brn-3a

Country Status (6)

Country Link
EP (1) EP1003859A1 (ja)
JP (1) JP2001511344A (ja)
AU (1) AU8548198A (ja)
CA (1) CA2298107A1 (ja)
IL (1) IL134210A0 (ja)
WO (1) WO1999005272A1 (ja)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9819999D0 (en) * 1998-09-14 1998-11-04 Univ London Treatment of cancer
EP1151094A1 (en) * 1998-12-07 2001-11-07 University College London Cervical cancer treatment
CA2443123A1 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
US7927597B2 (en) 2001-04-10 2011-04-19 Agensys, Inc. Methods to inhibit cell growth
KR100820072B1 (ko) * 2002-12-28 2008-04-10 (주)아모레퍼시픽 진세노사이드 F1을 유효성분으로 하는 Bcl-2 발현조절제
JP3870921B2 (ja) 2003-04-01 2007-01-24 セイコーエプソン株式会社 非接触識別タグ
KR100868905B1 (ko) * 2004-03-26 2008-11-14 (주)아모레퍼시픽 진세노사이드 f1과 egcg을 함유한 자외선 조사로유도되는 피부손상 방지용 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9615794D0 (en) * 1996-07-26 1996-09-04 Medical Res Council Mutant herpes simplex virus strains and uses thereof

Also Published As

Publication number Publication date
IL134210A0 (en) 2001-04-30
JP2001511344A (ja) 2001-08-14
WO1999005272A1 (en) 1999-02-04
WO1999005272A9 (en) 1999-10-28
EP1003859A1 (en) 2000-05-31
AU8548198A (en) 1999-02-16

Similar Documents

Publication Publication Date Title
Azmitia et al. S-100B but not NGF, EGF, insulin or calmodulin is a CNS serotonergic growth factor
Lamballe et al. trkC encodes multiple neurotrophin‐3 receptors with distinct biological properties and substrate specificities.
AU749017B2 (en) Mutant herpes simplex viruses and uses thereof
Attree et al. The Lowe's oculocerebrorenal syndrome gene encodes a protein highly homologous to inositol polyphosphate-5-phosphatase
JP5108797B2 (ja) 色素上皮誘導因子:pedf遺伝子の特性評価、ゲノム構成および配列
US6106826A (en) Replication competent, avirulent Herpes simplex virus as a vector for neural and ocular gene therapy
EP0938553B1 (en) Dna encoding dp-75 and a process for its use
JP2001508294A (ja) 真核細胞遺伝子発現カセットおよびその使用
CA2298107A1 (en) Use of transcription factor brn-3a
US7329741B2 (en) Polynucleotides that hybridize to DP-75 and their use
CZ288882B6 (cs) Polynukleotid, antimediátorový polynukleotid, polypeptid kódovaný uvedeným polynukleotidem, vektor obsahující uvedený polynukleotid, farmaceutická kompozice obsahující uvedený polynukleotid nebo antimediátorový polynukleotid nebo polypeptid nebo vektor a jejich použití pro přípravu farmaceutické kompozice
US7060429B2 (en) Treatment of neurodegenerative diseases by altering levels of TrkB isoforms and/or TrkC isoforms
US6194175B1 (en) Nucleic acids encoding truncated forms of inhibitory kappa B protein
EP1572887A2 (en) Neural regeneration peptide and methods for their use in treatment of brain damage
WO1997010349A1 (en) Materials and methods for treating neurodegenerative diseases and for screening for candidate apoptosis inhibitors and inducers
WO2005042561A2 (en) Neural regeneration peptides and methods of use
WO2003071872A1 (en) Novel treatment of neurodegenerative diseases by altering levels of trkb isoforms and/or trkc isoforms
Yang et al. Sustained expression of functional nerve growth factor in primary septo-hippocampal cell cultures by liposome-mediated gene transfer
WO1998019686A9 (en) Therapeutic methods for vascular injury
US20060148749A1 (en) Novel treatment of neurodegenerative diseases by altering levels of TrkB isoforms and/or TrkC isoforms
WO1999036559A1 (en) Viral vectors expressing self-polymerizing neuronal intermediate filaments and their use
EP0535337A2 (en) Cell growth inhibiting activities of heparin binding neurite-outgrowth promoting factor
EP0535336A2 (en) MK protein as cell growth inhibitor
WO2002067858A2 (en) Novel treatment of neurodegenerative diseases by altering levels of trkb isoforms and/or trkc isoforms
US5952213A (en) Src-family kinase and methods of use thereof

Legal Events

Date Code Title Description
FZDE Discontinued